A system-wide initiative in Sweden helped hospitals reduce readmission rates and shorten lengths of stay. When it came to heart failure patients specifically, however, the changes barely made an impact.
As one may expect, patient satisfaction was considerably higher for individuals who did not have to fast for a minimum of six hours prior to treatment. There were no other significant differences.
Highly anticipated trial data comparing mechanical thrombectomy to anticoagulation alone for intermediate- and high-risk pulmonary embolism showed that the more aggressive strategy improved outcomes.
Medicare claims submitted between 2017 and 2022 showed a 712% increase in thrombectomy for pulmonary embolism (PE) and a 137% increase in thrombectomy for deep vein thrombosis (DVT).
Former American College of Cardiology president Hadley Wilson, MD, executive vice chair of Atrium Health Sanger Heart and Vascular Institute, explains his main takeaway messages from the ACC 2025 late-breaking trials.
S. Chris Malaisrie, MD, professor of surgery at Northwestern University, explained what these data can tell us about the lifetime management of patients who require aortic valve replacement.
